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Abstract
Fluids and electrolytes are basic components of the human body and essential for the 
survival of most species. Any imbalance can potentially lead to serious conditions and 
death. The replacement of fluids and electrolytes has been used since the ancient age. 
Modern medicine still requires certain degree of expertise in these areas, which ranges 
from simple replacement in patients with mild illness to a more complex management 
in critically ill or hospitalized patients. Training and education in the evaluation and 
management of patients with fluids and electrolyte abnormalities are fundamental for 
patient’s outcomes. Severe sodium abnormalities are associated with increased morbid-
ity and mortality, and they are markers of poor outcomes. This review presents a concise 
discussion of frequently asked questions in the evaluation and management of patients 
with fluids and sodium abnormalities.
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1. Introduction
The serum sodium (sNa) concentration and thus serum osmolality (sOsm) are closely con-
trolled by water homeostasis, which is mediated by thirst, arginine vasopressin, and the 
kidneys. A disruption in this delicate balance is manifested as an abnormality in the sNa 
concentration—hyponatremia or hypernatremia and/or hemodynamic instability.
Fluid administration is an integral part of the clinician’s armamentarium to manage a wide 
variety of clinical conditions, which range from mild dehydration to more life-threatening 
conditions like shock or trauma.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The goal of this review is to provide a concise discussion regarding fluids and sodium imbal-
ance with an attempt to answer practical clinical questions on those areas. We focus in dis-
cussing basics physiological principles, and addressing the most common clinical challenges 
encountered by the practicing clinician.
1.1. Basic physiologic principle of fluids and sodium
The human body is composed of approximately 60% of water of which two-third are in the 
intracellular space and one-third in the extracellular space. The extracellular space is com-
posed by the intravascular compartment (~8%), the interstitial compartment (~25%) and the 
transcellular compartment like cerebrospinal, pericardial fluid, which is very small [1, 2]. In 
the healthy individual, the extracellular fluid (ECF) and intracellular fluid (ICF) are in osmotic 
equilibrium, water moves from areas of greater solute concentration to establish equilibrium. 
Additionally, osmotically active substance shifts water from lower osmolarity to higher osmo-
larity areas. This is an important concept to understand when we administer intravenous 
fluids (IVF), as the distribution of fluids is based on the type of fluid administered.
There is a delicate and complicated transport system of water through cell membranes to 
maintain fluids and electrolyte balance. Sodium is the predominant cation in the extracellular 
compartment, which is electro-neutralized by chloride (Cl) and bicarbonate (HCO
3
) as anions. 
In the intracellular space, potassium (K) is the major intracellular cation that is neutralized 
by many organic and nonorganic anions. The differential distribution of Na and K is tightly 
regulated by the sodium pump (Na-K ATPase) [1, 2]. Most osmotically active Na and K are 
dissolved and are sourced mostly from food intake. The body’s ability to store sodium in 
tissues (bone, cartilage, connective tissue, etc.) prevents large fluctuations in the sNa levels 
despite erratic sodium intake [3, 4]. Most of the components in the intracellular compartment 
are too large to be able to cross membranes exerting little osmotic pressure.
Estimating the ECF volume based on sNa is highly prone to errors in clinical judgment. The 
volume in both, intracellular and extracellular fluids is primarily determined by the concen-
tration of effective solutes that attract water by osmosis. Sodium and its attendant monovalent 
anions are the most prevalent effective solutes in ECF volume. The concentration of Na is 
determined by content of Na as well as volume of water. The primary tonicity receptor is 
located in the hypothalamic osmoreceptor, which is in charge to regulate the antidiuretic 
hormone (ADH) or vasopressin. The absence of ADH prevents aquaporin insertion on the 
luminal surfaces of collecting ducts in the nephrons forming hypotonic urine. The osmorecep-
tor is linked to both the thirst center and the vasopressin release center via nerve connections. 
There is a genetic susceptibility to hyponatremia linked to the gene coding for TRPV4 [2, 5–8]. 
Disease states releasing ectopic vasopressin or affecting vasopressin receptors will present 
with hyponatremia. Less prominent but important trigger for the regulation of vasopressin is 
large changes in effective arterial blood volume and blood pressure. Baroreceptors or stretch 
receptors in the carotid sinus and aortic arch are surrogates that detect changes in effective 
arterial blood volume. Nausea, pain, stress, and a number of other stimuli, including some 
drugs can also cause release of vasopressin [5].
Fluid and Electrolyte Disorders2
2. Fluids
Intravenous fluids are one of the commonest used medications in hospitalized patients. They 
can be broadly categorized as crystalloids and colloids. Crystalloid solutions contain water, 
electrolytes with or without glucose. Colloids solutions contain albumin, starch, or other 
blood products. Fluids can be isotonic, hypotonic, or hypertonic.
Crystalloids: Common crystalloid solutions include 0.9%-normal saline (NS), 0.45%NS, lac-
tated Ringers solutions (LR), Plasma-Lyte, and dextrose in water. Solutions with electrolyte 
compositions closer to that of plasma are called balanced fluids. Composition of commonly 
used crystalloids can be seen in Table 1.
Colloids: They can be divided into natural or synthetic. Natural colloidal solutions include red 
blood cells, fresh frozen plasma, and human albumin. Indications for the use of packed red 
cell and fresh frozen plasma are specific; they provide oxygen carrying capacity and clotting 
factors, respectively. Discussion regarding the use of red blood cells and plasma is beyond the 
scope of this review.
Synthetic colloidal solutions include hetastarch and dextran. They are used for volume expan-
sion and include hetastarch and dextran.
Colloids can be categorized as hypo oncotic (e.g., gelatins, 4 or 5% albumin) and hyper oncotic 
(e.g., dextrans, hydroxyethyl starches (HES), and 20 or 25% albumin) solutions. Table 2 
describes the composition of commonly used colloids.
Indications for the use of either crystalloids or colloids depend of the clinical condition. 
Volume expansion by fluids is dependent on their osmolality and oncotic pressure. Isotonic 
fluids will distribute equally to all fluid compartments without a significant shift across 
Solution Na+ 
(mEq/L)
Cl− 
(mEq/L)
K+ 
(mEq/L)
Ca++ 
(mEq/L)
Lactate 
(mEq/L)
Glucose 
(g/l)
pH Osmolarity 
(mOsm/L)
0.9%NS 154 154 0 0 0 0 pH 5.6 
(4.5–7.0)
308
0.45 saline 
(1/2 saline)
77 77 0 0 0 0 5.0 (4.5–7) 154
3% saline 513 513 0 0 0 0 5.0 (4.5–7) 1026
Ringers 
lactate
130 109 4 3 28 0 6.5 272
Plasma-Lyte 
A*
140 98 5 0 8 0 7.4 294
5% dextrose 0 0 0 0 0 50 5.0 260
*Also contains magnesium 3 mEq/L, acetate 27 mEq/L, gluconate 23 mEq/L.
Table 1. Composition of crystalloids.
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cellular or vascular planes. However, hypertonic solutions will move fluids from intracellular 
and interstitial space into the intravascular compartment, while hypotonic fluids will result in 
shift of fluids from intravascular space to interstitial and intracellular compartments. Volume 
expansion of the intravascular compartment with colloids depends on the oncotic pressure.
The most common clinical indications for fluid administration are:
• Replacement of volume losses
• Maintenance of fluids and electrolyte balance
• Correction of electrolyte or acid-base disorders
• Persistent hypoglycemia or hyperglycemia
• Provision of a source of fuel (glucose)
• Intravenous administration of medication.
2.1. Question 1: which fluids are more effective—colloids or crystalloids?
Fluid resuscitation in critically ill patients in shock is the mainstay of therapy to maintain 
effective circulating blood volume. Timing of fluid resuscitation plays an important role in 
resuscitation and is based on the pathophysiology of shock [9, 10]. A long-standing contro-
versy exists between proponents of colloids versus crystalloids for those patients. Supporters 
of crystalloids argue about risks of anaphylaxis, hemostasis impairment, and need for renal 
replacement therapy (RRT) with colloids as well as the potential to accumulate in tissues; 
whereas the colloid proponents argue with the risk of edema associated with crystalloids.
A recent Cochrane analysis concluded that there was no difference in mortality for hospitalized 
patients with trauma, burns, or following surgery when colloids were compared with crystal-
loids [11]. The use of HES may be associated with increased mortality; when they are compared 
to crystalloids, there was a higher incidence of adverse events and need for RRT [12, 13].
In the Crystalloid versus Hydroxyethyl Starch Trial (CHEST), involving 7000 adults in the 
ICU, the use of 6% HES (130/0.4), as compared with 0.9NS, was not associated with a signifi-
cant difference in the rate of death at 90 days.
Fluid Na+ (mEq/L) Cl− (mEq/L) Colloidal oncotic pressure 
(mm Hg)
Osmolarity (mOsm/L)
Albumin 5% 130–160 130–160 20 308
Albumin 25% 154 154 100 308
Hetastarch (6%)-NaCl 154 154 30 310
Gelatins (gelofusine 4%) 154 154 33 310
Dextran 70 + NaCl 154 154 60 310
Table 2. Composition of colloids.
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However, there was an increase in the rate of RRT and more adverse events in HES group 
[12]. The Colloids versus Crystalloids for the Resuscitation of the Critically Ill (CRISTAL) 
trial compared the effects of colloids versus crystalloids on mortality in patients presenting 
with hypovolemic shock [14]. There was no difference in mortality between the two groups at 
28 days although 90-day mortality was lower in patients receiving colloids.
Low albumin levels are associated with all-cause mortality in both medical and surgical 
patients [15, 16]. Contrary to the belief that using albumin as a resuscitation fluid could 
improve mortality, a Cochrane review of 24 studies involving a total of 1419 patients, sug-
gested that administration of albumin-containing fluids resulted in a 6% increase in the abso-
lute risk of death when compared with use of crystalloid solutions [17]. This lead to the SAFE 
trial that showed similar outcomes between albumin and 0.9NS for resuscitation [18] No trial 
has consistently revealed superiority of albumin over crystalloids as resuscitative fluid.
In summary, there is no advantage of colloids versus crystalloids or vice versa. Considering 
the cost and adverse effect profile of colloids, crystalloids may be preferred over colloids. 
When colloids are used, care must be taken not to exceed recommended dose by regulatory 
agencies and avoid their use in patients with renal failure.
2.2. Question 2: are balanced fluids better than “0.9 normal saline?”
Normal saline is also referred as physiological or isotonic saline, neither of which is accurate. 
The sodium and chloride concentration of 154 mEq/L and the pH of 5.6 are certainly abnormal 
in “normal saline.” The strong ion difference (SID) is the difference between the positively- 
and negatively-charged strong ions in plasma. Disturbances that increase the SID increase the 
blood pH while disorders that decrease the SID lower the plasma pH. This may also occur 
with volume resuscitation with 0.9NS (>30 cc/kg/h) due to excessive chloride administration 
impairing bicarbonate resorption in the kidneys resulting in hyperchloremic metabolic acido-
sis [19]. Other potential effects of 0.9NS include renal vasoconstriction with worsening renal 
function [20], increased postoperative complications, coagulation abnormalities [21], and an 
increased risk of death [22–24].
Lactated ringer, Plasma-Lyte, and Normosol are often called ‘balanced fluids’ as their electro-
lyte contents are closer to human plasma. These balanced crystalloids are also nearly isotonic 
but have a chloride concentration less than 110 mEq/L and a SID close to plasma.
Several trials comparing 0.9NS to balanced fluids have reported multiple outcomes. 
Outcomes have ranged from renal failure to mortality. Among critically ill adults with sep-
sis, resuscitation with balanced fluids was associated with a lower risk of in-hospital mortal-
ity [25]. In a meta-analysis of 11 RCTs (8 trials in operation room and 3 in ICU) involving 
2703 patients, the in-hospital mortality, occurrence of acute kidney injury (AKI), and need 
for RRT was not different between balanced solutions and 0.9NS, irrespective of the loca-
tion of the patients [26]. In a before and after trial comparing 0.9NS with LR solution, use 
of saline was a safe, viable alternative to LR in the trauma population [27]. In ICU patients 
requiring crystalloid fluid therapy, the use of a buffered crystalloid compared with saline 
did not reduce the risk of AKI or mortality [28]. Data regarding best fluid for the periop-
erative period is still inconclusive [29]. In patients undergoing renal transplants, balanced 
Fluids and Sodium Imbalance: Clinical Implications
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electrolyte solutions were associated with less hyperchloremic metabolic acidosis compared 
to 0.9NS, but there were no difference in graft outcomes [30]. Among critically ill adults, the 
use of balanced crystalloids for IVF administration resulted in a lower rate of the composite 
outcome of death from any cause, new RRT or persistent renal dysfunction when compared 
to 0.9NS [31] Among noncritically ill adults treated with IVFs in the emergency department, 
there was no difference in hospital-free days between treatment with balanced crystalloids 
compared with saline [32].
Some myths about Ringers lactate:
1. Ringers lactate in renal failure: In a study comparing acid-base status in kidney transplant 
patients, LR compared with 0.9NS may lead to a lower serum potassium level and a 
lower risk of acidosis [33]. In a randomized, double-blind comparison of LR’s solution 
and 0.9%NS during renal transplantation, LR was associated with less hyperkalemia and 
acidosis compared with 0.9NS [34].
2. Ringers lactate in hepatic failure: LR is avoided in patients with hepatic failure with the fear 
of inducing or worsening lactic acidosis. However, lactate is given as sodium lactate, which 
is a base rather than an acid. There are no data describing LR causing worse outcomes 
compared to saline in patients with hepatic dysfunction.
In summary, 0.9%NS is not superior to balanced fluids in volume resuscitation in both criti-
cally ill and noncritically ill patients, perioperative patients and posttrauma. Studies suggest 
that use of balanced crystalloids for IVF administration results in a lower rate of the composite 
outcome of death from any cause, new RRT, or persistent renal dysfunction than the use of 
0.9%NS in critically ill patients. Balanced fluids are not harmful compared to 0.9%NS and seem 
to be the fluid of choice. However, caution is advised when balanced solutions are used in 
patients with renal failure and hyperkalemia. Normal saline is an ideal choice in patients with 
metabolic alkalosis and chloride deficits who are vomiting or have nasogastric tube to suction.
2.3. Question 3: what are the common indications for hypertonic saline?
The classical indication for 3% saline is symptomatic severe hyponatremia. This is discussed 
in detail later in this chapter. Other indication for hypertonic saline is resuscitation in patients 
with traumatic brain injury (TBI). In patients with TBI, osmotic agents to reduce cerebral 
edema are recommended [35]. Common osmotic agents are mannitol and hypertonic saline. 
Hypertonic saline decreases intracranial pressure (ICP), improves microcirculation, and acts 
as anti-inflammatory [36]. A retrospective study comparing effectiveness of mannitol versus 
hypertonic saline revealed that hypertonic saline given in boluses may be more effective than 
mannitol in lowering ICP but no difference was found in short-term mortality [37]. A com-
parison of effects in coagulation function or increase in the risk of intracranial rebleeding in 
patients with moderate TBI when using 3% hypertonic saline versus 20% mannitol for the 
control of ICP showed no differences [38]. A comparison of pharmacologic therapeutic agents 
used for the reduction of intracranial pressure after traumatic brain injury concluded that 
hypertonic saline exhibits beneficial advantages compared with the other medications as a 
first-line treatment of intracranial hypertension in patients with severe TBI [39]. Complications 
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of hypertonic saline use include hypernatremia, hyperchloremia, and renal failure. Mannitol 
and hypertonic saline in equiosmolar concentrations produced comparable effects on ICP 
reduction, brain relaxation, and systemic hemodynamic [40].
Hypertonic saline has been advocated in patients with volume loss after trauma, whereas 
TBI seems to be an indication to decrease cerebral edema, use of hypertonic saline in other 
situations is still unclear. In a meta-analysis, use of hypertonic saline showed no differences 
in clinical outcomes for hypotensive injured patients compared to isotonic fluid in the prehos-
pital setting [41]. There is no evidence that hypertonic saline provides any additional benefit 
over isotonic crystalloid solutions for trauma resuscitation [42].
In summary, hypertonic saline can be used to decrease intra cranial pressure in patients with 
moderate to severe TBI. Care must be taken to avoid hypernatremia, hyperchloremia, and 
renal failure.
2.4. Question 4: how do we manage fluids in sepsis and septic shock?
In severe sepsis and septic shock, early volume resuscitation is indicated to save lives [43–45]; 
however, the best choice of fluids is unclear.
In a multicenter ICU trial of patients with severe sepsis randomly assigned to either 6% HES 
130/0.42 or ringers acetate, patients receiving 6% HES 130/0.42 had a significant increase in the 
rate of death at 90 days and need for RRT. Several meta-analyses have shown that albumin 
does not provide a mortality benefit or decrease the need for RRT in critically ill patients, 
including those with hypoalbuminemia and sepsis [46–48]. A recent trial comparing albumin 
in addition to crystalloids versus crystalloids alone did not confer survival benefit in patients 
with severe sepsis or septic shock [49].
The early 2000s saw a resurgence in the use of hypertonic saline for sepsis resuscitation. Small 
volume resuscitation with hypertonic saline was postulated to achieve hemodynamic nor-
malization by recruitment of fluid from the intracellular space, limiting interstitial edema 
[50]. Additional advantages included improved microcirculatory flow and favorable immu-
nomodulatory effects. Two clinical trials have investigated the use of hypertonic saline in 
adult septic patients and there was no mortality difference [51, 52].
In the risk-adjusted inverse probability weighting analyses including 60,734 adults admitted to 
360 ICUs across the United States between January 2006 and December 2010, the hospital mortal-
ity was 17.7% in the balanced fluid group, 19.2% in the 0.9%NS plus balanced fluids plus colloid 
group, 20.2% in the 0.9NS group ,and 24.2% in the saline plus colloid group. Balanced crystalloids 
were consistently associated with lower mortality. The authors concluded that when compared 
with exclusive use of 0.9%NS during resuscitation, coadministration of balanced crystalloids is 
associated with lower in-hospital mortality and no difference in LOS or costs per day. When 
colloids are coadministered, LOS and costs per day are increased without improved survival [53].
In summary, balanced fluids may be preferred over 0.9%NS in the resuscitation of patients 
with severe sepsis or septic shock without renal/liver or potassium issues. Hypertonic saline 
and other colloids including albumin are likely of no benefit over crystalloids. Use of starch is 
associated with adverse effects including increased need for RRT.
Fluids and Sodium Imbalance: Clinical Implications
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2.5. Question 5: fluid management in diabetic ketoacidosis
Patients with diabetic ketoacidosis (DKA) present with high anion gap metabolic acidosis, 
dehydration, and fluid deficits. Caution is advised in use of 0.9%NS due to two reasons. First, 
cerebral edema is a risk factor for death in patients with DKA. When a saline bolus is admin-
istered, it will distribute initially in the plasma that reaches the blood-brain barrier before 
equilibrating with the extracellular compartment. This has the potential to increase the inter-
stitial volume of the brain ECF compartment and leads to cerebral edema. Second, chloride 
load in 0.9%NS can trigger nonanion gap metabolic acidosis.
A large bolus of 0.9%NS should be given only in emergent situations. It is advised to limit 
the amount of sodium ions infused in the first 120 min of therapy to about 3 mmol/kg body 
weight.
In a multicenter retrospective analysis of adults admitted for DKA to the ICU, which received 
almost exclusively Plasma-Lyte or 0.9%NS infusion up to 12 h, patients with PL had faster 
initial resolution of metabolic acidosis and less hyperchloremia, with a transiently improved 
blood pressure profile and urine output [54].
In summary: caution should be used using 0.9%NS in DKA and it is prudent to limit its use. 
If continued fluid resuscitation is needed, choice of fluids should be based on sNa levels. In 
patients with eunatremia or hypernatremia 0.45%NS is preferred and should be infused at 
4–14 ml/kg/h, 0.9%NS is preferred in hyponatremia patients [55, 56].
2.6. Question 6: does my patient need maintenance fluids?
Maintenance fluid therapy is indicated in patients who are unable to eat for prolonged period of 
time in order to provide for fluids, electrolytes, and possibly some nutrition. The goal is to pro-
vide enough fluid and electrolytes to meet insensible losses and enable renal excretion of waste 
products. On an average, 2500 ml of water is ingested daily of which 60% is in form of fluids. 
Maintenance fluids should be a short-term measure since inappropriate therapy risks volume 
overload and electrolyte and acid-base disturbance. It is recommended to use 25–30 ml/kg/day 
water, 1 mmol/kg/day sodium, potassium, chloride, and 50–100 g/day glucose daily [57].
Higher insensible losses and hence higher maintenance of fluids needs to be considered in 
patients with ongoing losses, fever, burns, and third space losses especially in post-operative 
surgical patients. There is no evidence to use one kind of crystalloids over the other, hypo-
tonic solutions should be avoided to avoid hyponatremia and avoidance of excessive sodium 
overload with 0.9%NS. Monitoring and avoidance of development of electrolyte imbalance 
is critical. Daily weights will prevent volume overload. Continuation of maintenance fluids 
should be critically reviewed in a daily bases.
2.7. Question 7: is there an ideal IV fluid?
An ideal resuscitative fluid should have an electrolyte composition close to plasma, should 
not accumulate in tissue, and must be completely metabolized. An ideal fluid does not exist 
and fluids should be treated as any other medication—indications, duration, effects, and 
adverse effects. Deciding which fluids are appropriate for each patient depends on the type 
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of fluid lost and the body compartment(s) that require additional volume. It is advisable to 
consider patients comorbid conditions, acid-base and electrolyte status, and the indication for 
fluids before making a final selection. Timing of therapy is based on clinical context, delayed 
resuscitation is not only resuscitation denied but could have a detrimental effect.
Education of use of fluids to the health care providers, especially those who usually initiate 
care on hospital admission is paramount to improve outcomes and decrease morbidity and 
mortality.
Pearls:
1. Treat IVF like medications and consider risks, benefits, alternatives, and risks of alternatives.
2. In most instances, balanced solutions may be adequate.
3. Normal saline is probably the fluid of choice in patients with metabolic alkalosis due to 
vomiting or gastrointestinal losses with volume and chloride deficits.
4. In critically ill adults, the use of 0.9%NS for IVF administration results in a higher rate of 
the composite outcome of death from any cause, new RRT, or persistent renal dysfunction.
5. In patients with DKA, use of 0.9%NS should be restricted to 1–1.5 L unless a compelling 
indication.
6. Hypertonic saline or colloids are fluids of choice in TBI with cerebral edema.
7. Role of hypertonic saline in trauma other than TBI, severe sepsis, septic shock, and hem-
orrhagic shock is uncertain.
8. HES is a risk factor for renal injury and need for RRT.
9. If a synthetic colloid is chosen, do not exceed the manufacturer recommended maximal dose.
10. Use maintenance fluids only when indicated and review need daily.
3. Disorders of sodium imbalance
3.1. Hyponatremia
3.1.1. Question 8: what is the importance of hyponatremia?
Hyponatremia is a common laboratory abnormality; it is usually defined as a sNa of less than 
136 mmol/L. The sNa cut offs to define hyponatremia varies from 125 to 135 mmol/L depend-
ing on different studies [58, 59].
Hyponatremia have been reported in 8% of the general population and in up to 60% of hospi-
talized patients [60]. Patients in ambulatory setting have a lower rate compared with hospital 
or skill nursing facility setting. Miller et al. reported an 11% incidence of hyponatremia in the 
ambulatory setting among elderly population with a median age of 78 years [61, 62].
The importance of hyponatremia is related not only to the absolute sNa value, but to the 
underlying conditions leading to it; it can be the tip of a serious condition. Severity of 
Fluids and Sodium Imbalance: Clinical Implications
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hyponatremia or its management can impact the patient’s outcomes. Hyponatremia is not a 
disease, but a manifestation of an underlying disorder. The main focus of the management 
of hyponatremia is to elucidate the etiology and correction of laboratory abnormalities when 
levels are life threatening [59, 63].
Two major international guidelines attempted to address best practices in the management 
of this condition. The United States guidelines were published in 2013, however, they did 
not include grade of evidence due to scarce clinical evidence and resorted to expert panel 
recommendations [64]. In 2014, the European guidelines were published and included qual-
ity of evidence grades [65–67]. Rather than the absolute value of the sNa levels, the acuity of 
development of hyponatremia and its correction are of prime importance because the rate 
of change in sNa levels is associated with mortality, morbidity, and LOS [68, 69]. Mortality 
associated with hyponatremia has been reported as high as 30% [69].
A summary of relevant publications addressing prevalence of hyponatremia can be seen in 
Table 3. The serum cut off values for sodium in all those studies was between 130 and 138 and 
most of the studies were randomized control studies [58, 59].
3.2. Classification
Hyponatremia can be classified based in:
• Severity: this is based only in the absolute level of sNa. Mild 130–135 mmol/L, moderate 
125–130 mmol/L, and severe when sNA is lower than 125 mmol/L.
• Time interval of development: acute-less than 48 h and chronic if more than 48 h. This 
information is occasionally difficult to obtain, but causes are usually different for acute and 
chronic hyponatremia.
• Measured osmolarity: it is fundamental to differentiate between the true hypotonic state from 
the isotonic and hypertonic state. Isotonic hyponatremia is usually due to pseudohypona-
tremia secondary to high plasma concentrations of triglycerides or proteins [70]. Expected 
changes in sNa in hypertriglyceridemia (TG) can be calculated as TG × 0.0002 = decrease in 
sNa in mEq/L; for plasma proteins (PP), PP in gm/dl – 8 × 0.25 = decrease in sNa in mEq/L.
Commonest causes of hypertonic hyponatremia are hyperglycemia, administration of 
mannitol or other agents; the osmotic shift of water from ICF to ECF increases the total 
plasma volume diluting the sNa levels. Each increase in serum glucose levels by every 
100 mg/dl after 150 mg/dl, decreases the sNa by approximately 1.6 mmol/L [71].
• Volume status: hypovolemia, euvolemia, and hypervolemia [72]. This is the most com-
mon classification used in the United States [64]. However, this classification is intrinsically 
flawed as there are no reliable, readily available and highly sensitive clinical tools to dif-
ferentiate volume status, especially to differentiate hypovolemia from euvolemia [73–75]. 
Euvolemia itself is considered to be a misnomer as loss of sodium cannot happen without 
loss of water [2]. Clinical assessment is more reliable in cases of hypervolemia [2].
Erroneous classification of patients into these categories can have detrimental outcomes [76].
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3.3. Clinical features
Symptoms of hyponatremia are initially subtle, nonspecifics, and difficult to recognize. They 
mostly manifest as neurological changes, which ranges from altered personality, lethargy 
and confusion to seizures, coma and death in severe cases [2, 77]. Symptomatic differences 
between acute severe and chronic hyponatremia have been reported. Symptoms of acute 
severe hyponatremia include nausea, vomiting, headache, seizure, coma, respiratory failure, 
and death, which are manifestations of brain edema. In chronic hyponatremia, main symp-
toms are fatigue, gait and attention deficit, osteoporosis, and fractures. Nausea and vomit-
ing are seen in both, acute severe and chronic hyponatremia [78, 79]. Older patients with 
comorbid conditions tend to develop symptoms of hyponatremia at an earlier onset than 
young healthier patients. Premenopausal women are prone for cerebral edema from acute 
hyponatremia, it is hypothesized that this could be secondary to the action of estrogen and 
progesterone inhibiting Na+K+-ATPase and decreasing solute expel from brain cells; if not 
Reference Frequency (%) Sample size Outcome
Ambulatory setting
Hawkins et al. 0.14 24,027 NA
Liamis et al. 7.7 5179 ↑ Mortality
Gankam Kengne et al. 6 3551 ↑ Mortality
Mohan et al. 2.5 14,697 NA
Hospital
Hawkins et al. 42.6 43,249 NA
Hoorn et al. 30 5437 NA
Wald et al. 30 34,761 ↑ Mortality
Wakar et al. 14.5 98,411 ↑ Mortality
Congestive heart failure
Gheorghiade 20 47,647 ↑ Mortality
Liver cirrhosis
Angeli et al. 49 997 ↑ Mortality
Dawas 11 5152 ↑ Mortality
HIV infection
Tang 38 259 ↑ Mortality
Cusano et al. 31 96 ↑ Mortality
Non-dialysis kidney failure
Covesdy et al. 13 655,493 ↑ Mortality
Pneumonia
Zilberberg et al. 8 7965 ↑ Mortality
Modified from [58, 59].
Table 3. Prevalence and outcome of hyponatremia.
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recognized early, it will lead to neurological complications. The nonneurological manifesta-
tions are often due to the dysregulation in the volume status [5, 80].
3.3.1. Question 9: what are the causes of hyponatremia?
The best approach to evaluate causes of hyponatremia is to first decide if we are dealing with 
acute versus chronic hyponatremia.
Acute hyponatremia: the underlying etiological mechanism primarily causes large input of 
water. Normal individuals with intact thirst center and mental function develop aversion to 
large volume water intake. Table 4 shows most common causes of acute hyponatremia.
Chronic hyponatremia: slow onset of hyponatremia, usually more than 48 h. The underlying 
etiology is lower rate of water excretion and involves release of vasopressin. In some case, 
decreased volume of filtered solute and residual water permeability play a role [5]. Table 5 
shows most common causes of chronic hyponatremia and Table 6 shows the most common 
laboratory findings in the most common causes of hypotonic hyponatremia.
3.3.2. Question 10: how we evaluate a patient with hyponatremia?
Evaluation of hyponatremia still remains to some extent controversial and occasionally 
cumbersome.
In an attempt to avoid the pitfalls of volume evaluation recommended in the 2012 guidelines, 
the European guidelines were released in 2014. They prioritized the use of urine sodium 
(uNa) levels and urine osmolality (uOsm) over assessment of volume status [67]. Conditions 
leading to a false low or high uNa levels like low sodium diet or recent diuretic use and 
chronic kidney disease respectively were addressed [66, 81, 82].
Role of vasopressin and copeptin levels: measurement of vasopressin levels seems logical for the 
investigation of hyponatremia, but its unstable nature when not bound to plasma, low accu-
racy, and not readily available makes it use unsuitable. Moreover, uOsm is a readily avail-
able, accurate, and inexpensive surrogate [83]. Vasopressin is degraded into neurophysin and 
copeptin by enzymatic cleavage. Copeptin has been considered also a reasonable surrogate for 
Ingestion of large volume 
of water
Infusion of large volume of 
5% dextrose
Infusion of large volume 
of hypotonic lavage fluid
Generation and retention 
of electrolyte-free water 
(“desalination”)
• Mood-altering drugs 
which blocks aversion 
to large water intake
• Increased water intake 
to avoid dehydration
• Beer potomania
• Psychotic state
• Postoperative period 
(especially patients with a 
low muscle mass)
• Input of water and 
organic solutes, with 
little or no Na+ ions 
(e.g. post transurethral 
resection of prostate)
• Excretion of large 
volume of hypertonic 
urine caused by a large 
infusion of isotonic 
saline in a setting where 
vasopressin is present
Table 4. Causes of acute hyponatremia.
Fluid and Electrolyte Disorders12
vasopressin. Copeptin levels were reported to be increased in hypo and hypervolemic hypo-
natremia but not in syndrome of inappropriate secretion of antidiuretic hormone (SIADH). A 
ratio of serum copeptin to uNa with a cut off value of 30 pmol/mmol had an AUC of 0.88 in 
identifying hypovolemia from euvolemia [84].
Lower rate of water excretion due to low 
volume of distal delivery of filtrate
Lower rate of water excretion due to vasopressin actions
• Very low glomerular filtration rate 
states
• States with enhanced reabsorption 
of filtrate in the proximal collecting 
tubules caused by low effective 
arterial blood volume
• Loss of Na+ and Cl−
• Sweat: cystic fibrosis, marathon 
runner
• Gastrointestinal tract: diarrhea
• Renal: diuretics, aldosterone defi-
ciency, renal or cerebral salt wasting
• States with expanded extracellular 
fluid volume but low effective arte-
rial blood volume (e.g., congestive 
heart failure, liver cirrhosis)
• Non-osmotic stimuli: pain, anxiety, nausea
• Baroreceptor-mediated release of vasopressin due to very low EABV
• Central stimulation of vasopressin: drugs like 3,4-methylenedioxy-
methamphetamine (MDMA), nicotine, morphine, carbamazepine, 
tricyclic antidepressants, serotonin reuptake inhibitors, antineoplastic 
agents
• Pulmonary disorders: bacterial or viral pneumonia, tuberculosis
• Central nervous system disorders: encephalitis, meningitis, brain 
tumors, subdural hematoma, subarachnoid hemorrhage, stroke
• Release of vasopressin from malignant cells: small-cell carcinoma of 
the lung, oropharyngeal carcinomas, olfactory neuroblastomas
• Administration of desmopressin
• Glucocorticoid deficiency
• Severe hypothyroidism
• Activating mutation of the vasopressin 2 receptor: nephrogenic 
syndrome of inappropriate antidiuresis
Modified from [5].
Table 5. Causes of chronic hyponatremia.
Volume status Clinical conditions Urine Osm Urine Na Serum uric acid FE
NA
Hypovolemic 
(appropriate ADH 
response)
Extrarenal losses Elevated <10–20 Elevated >4 <1
Renal losses deficiency of 
mineralocorticoids
Elevated >20 Elevated >1
Hypervolemic 
(appropriate ADH 
response)
Heart failure, liver cirrhosis, 
nephrotic syndrome
Elevated <20 Low/normal <1
Renal failure Decreased >20 Variable >1
Euvolemia Reset osmostat Variable
SIADH Elevated 
>100–300
>30–40 Decreased <4 >1
Primary polydipsia Decreased Decreased Low/normal >1
Hypothyroidism, deficiency 
of mineralocorticoids
Elevated >20 Low/normal >1
Table 6. Laboratory findings in most common causes of hypotonic hyponatremia.
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Other biomarkers like apelin and midregional proatrial natriuretic peptide (MR-ProANP) 
have been evaluated in hyponatremia. Apelin counteract vasopressin in homeostasis. 
MR-ProANP increases to a larger extent in hypo or hypervolemic hyponatremia rather than 
in SIADH. The true diagnostic potential of these biomarkers are yet to be validated [85–88].
Based on existing guidelines and trying to overcome limitations of clinical evaluation of vol-
ume status, we suggest the following steps when evaluating a patient with hyponatremia:
1. Measurement of serum osmolarity to differentiate between hypotonic hyponatremia from 
iso- and hypertonic.
2. Hypotonic hyponatremia: clinical evaluation of volume status. In general, identification of 
hypervolemia is more accurate than differentiating between euvolemic and hypovolemic 
state.
3. Measurement of urine osmolarity (uOsm) and urinary sodium (uNa). This is conjunction 
with sOsm and examination should narrow down the diagnosis. For example, a threshold 
of uOsm of >100 mOsm/kg predicts the action of ADH on the collecting tubules, which in 
case of hyponatremia is not the appropriate response. This together with elevated uNa 
>20–30 mmol/L strongly suggests the presence of SIADH [2].
4. Needs to consider the presence of more than one disorder leading to hyponatremia [89].
5. Management should ideally address correction of sNa levels as well as the underlying 
condition leading to it.
6. Delayed or unavailability of sOsm is one of the major limiting factors during evaluation of 
hyponatremia as addressed by the United States guidelines, potentially leading to misclas-
sification of patients based on clinical assessment of volume status.
7. Some experts suggest that a limited work up including sOsm, uNa, uOsm, and infusion 
of isotonic saline 1–2 l over 24 h may be sufficient for an accurate diagnosis in most cases 
of hypotonic hyponatremia [2]. Increase in sNa after trial of volume expansion suggests 
hypovolemic hyponatremia. However, this can be also seen in SIADH [75, 90–92].
Volume expansion should be cautiously done in certain conditions like immediate post-
operative period, where isotonic saline can worsen the hyponatremia by a process called 
desalination, as presence of vasopressin makes the urine hypertonic by water resorption [93]. 
In addition, patients with hypervolemic states like heart failure or liver cirrhosis could dete-
riorate with the additional fluid administration.
Figure 1 shows a flow diagram for initial evaluation of hyponatremia.
3.3.3. Question 11: how do we manage hyponatremia?
Goal should ideally focus in the prevention of hyponatremia knowing its association with 
significant morbidity and mortality. There is no data available regarding the effects of treating 
asymptomatic mild to moderate hyponatremia [2, 94, 95].
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Patients presenting with severe, acute, or chronic hyponatremia should be treated in a monitor 
setting as those patients are at risk for adverse outcomes [2]. Acute respiratory failure from dam-
age of the respiratory center or noncardiogenic pulmonary edema has been reported [96, 97]. 
Identification of patients at higher risk for osmotic demyelination remains a challenge during 
treatment; risks factors for development of osmotic demyelination include presence hypokale-
mia, alcoholism, malnutrition, and liver disease [64, 98]. Table 7 shows basic management of 
patients presenting with hyponatremia and comparison of the two major existing guidelines.
Areas of concern with guidelines: caution must be excised when following guidelines. Areas 
of concern in the management of hyponatremia are:
• There is no clear evidence regarding the 48 h cut off to differentiate between acute and 
chronic hyponatremia, neither to clearly differentiate risk for osmotic demyelination in 
those patients.
• Clinically difficult to be certain regarding acuity of hyponatremia; in asymptomatic patients 
with hyponatremia, it could be assumed to be chronic.
• Limited evidence regarding the best and safer correction rate. A lower correction rate of 
6 mEq/L/24 h could be safer.
• When to treat a patient with mild to moderate hyponatremia and none/minimal neurological 
symptoms remain a gray zone and depends on the clinical situation. Fluid restriction is the 
most common, cost effective, and safer modality of treatment [2, 72]. Fluid restriction of 500–
1000 ml/day has been suggested and should be based in volume assessment. Urine Na to serum 
Figure 1. Algorithm for initial evaluation of hyponatremia. Based in the USA and European guidelines [64–67].
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electrolyte ratio (uNa + urine K/sNa) >1 indicates antidiuretic phase and a ratio <1 suggests 
aquaretic phase. Fluid restrictions to less than 500 ml/day in antidiuretic phase and 1000 ml/day 
in aquaretic phase have been recommended; however, adherence is a problem [72].
• Use of Vaptans. Vaptans are vasopressin type 2 receptor antagonist, present in the collecting 
duct and they induce excretion of hypotonic urine. Its use has been recommended in a sub-
group of patients with hyponatremia secondary to excess vasopressin [99, 100]. There are many 
vaptans available including tolvaptan, satavaptan, lixivaptan, and conivaptan, which are been 
successful at increasing sNa and relieving symptoms in conditions like SIADH, congestive heart 
failure, and liver cirrhosis [101–103]. Sodium overcorrection is a concern and it was reported in 
25% of 61 patients included in a study [103]. Side effects including liver injury, risk of overcor-
rection, and lack of long-term sodium improvement are some of limitations [101, 102, 104].
• Demeclocycline and lithium have low quality evidence to support front line management 
of hyponatremia. Demeclocycline is thought to inhibit adenylate cyclase activity upon 
binding of vasopressin to its receptor in the collecting tubule. The adverse effects associated 
with the drugs make them less desirable for treatment [2, 105].
3.3.4. Question 12: what are the complications and outcomes of hyponatremia?
Complications of hyponatremia can be divided in those caused by hyponatremia per se and 
those caused by the treatment of hyponatremia. In general, worse outcomes are associated 
with sNa levels of less than 115 mEq/L and with faster rate of fall in sNa [2].
3.4. Complications and outcomes of untreated hyponatremia
Complications of hyponatremia range from chronic debilitating symptoms like gait deficit 
and neuromuscular symptoms to a more severe and life-threatening presentation of brain 
edema. Chronic and mild-moderate hyponatremia have been associated with attention or gait 
deficits, increased risk of falls, and bone fractures. Bone is a reservoir for Na. Observational 
retrospective cross sectional and epidemiological surveys have established an association 
between chronic hyponatremia and osteoporosis and major osteoporotic fracture [106–111].
Unfortunately, there is a lack of evidence to suggest that osteoporosis is reversed with correc-
tion of hyponatremia [2].
The brain which is contained in the hard skull is not able to accommodate any swelling or 
increase in brain volume. This is evident especially in patients who develop acute hypona-
tremia. Cerebral edema occurs when cells within the brain swell, when there is an increase in 
extracellular fluid volume in the brain or both. Brain cells swell when there is a large osmotic 
force favoring an intracellular shift of water, owing to a higher effective osmolality in brain cells 
than the effective osmolality in plasma in capillaries near the blood–brain barrier [112–115]. 
The elevated intracranial pressure with the resultant acute cerebral edema can potentially lead 
to serious symptoms that ranges from seizures, coma to brain herniation causing irreversible 
midbrain damage and death [116, 117]. Incidence of fatal brain damage secondary to severe 
hyponatremia is unknown, majority of the cases have been reported during the perioperative 
period secondary to infusion of hypotonic fluids or self-water intoxication like marathon run-
ners and psychiatric patients [118].
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Most cases of hyponatremia in the ambulatory setting are mild. An sNa of less than 125 mmol/L 
was seen in 0.14% in Hawkin et al. study [60]. The Dallas heart study, a large prospective mul-
tiethnic cohort study of 3551 ambulatory individuals with median age of 43 year/age and from 
diverse ethnicity, found that mild hyponatremia (median 133 mmol/L) was significantly associ-
ated with increased risk of death [119]. A large cross sectional observational study by the National 
Health and Nutrition Examination Survey in the United States with 15,000 individuals demon-
strated that hyponatremia was an independent risk for increased mortality across age, gender, 
and comorbid conditions. Overall prevalence was around 2%. They also showed that prevalence 
of hyponatremia increased with age and was more frequent among women than men [120].
Others studies looking at the association of hyponatremia with specific comorbid conditions 
like heart failure, HIV, pneumonia, renal failure among others, concluded that hyponatremia 
is an independent risk factor for mortality regardless the levels of sNa [58, 121–129]. Among 
Conditions General agreement in guidelines Disagreement between guidelines
Acute or symptomatic 
hyponatremia—less 48 h
Severe symptoms: bolus 3% NaCl: 100–150 ml 
over 10–20 min × 2–3 as needed
Minimal—just in amount of fluids
50 ml difference
Moderate symptoms: continuous infusion 
3% NaCl 0.5–2 ml/kg/h or bolus 3% NaCl: 
100–150 ml over 20 min × 1
Chronic hyponatremia—
more 48 h
SIADH First line: fluid restriction None
Second line: demeclocycline, urea, or vaptan European guidelines do not 
recommend vaptans when sNa > 130 
and recommend against when 
sNa > 125.
Recommends against demeclocycline
Suggest oral NaCl or loop diuretics
Hypovolemic hyponatremia Isotonic saline or balanced crystalloid 
solution
Minimal/none
Hypervolemic hyponatremia Fluid restriction—500—1 L/day
Vaptans
European guidelines recommend 
against vaptan
Correction rates Minimum-only USA guidelines: 4–8 mmol/L/
day, 4–6 mmol/L/day in high risk of 
neurological complications
European guidelines have no 
minimum
Limits: 10–12 mmol/L/day, 8 mmol/L/day in 
high risk patients
None
Management of 
overcorrection
Baseline sNa ≥ 120 mmol/L: probably 
unnecessary
European guidelines suggest to start 
once limit is exceeded
Baseline sNa < 120 mmol/L: relower with 
electrolyte-free water or desmopressin after 
correction exceeds 6–8 mmol/L/day
Expert consultations recommended by 
European guidelines
Modified from [72].
Table 7. Management of hypotonic hyponatremia and comparison between existing guidelines.
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patients presenting with acute pulmonary emboli, hyponatremia is common and several 
studies has shown to be an independent risk factor for increased short-term mortality. This 
result could be encountered as a variable in determining of pulmonary emboli severity and 
mortality [130, 131].
Among the hospitalized population, many studies have estimated the prevalence of hypona-
tremia from 8 to 40% [60, 69, 89, 132]. In Wald et al. study evaluating more than 50,000 patients, 
he established that irrespective of onset of hyponatremia-community, hospital aggravated or 
hospital acquired, all were associated with increased mortality, length of stay, and discharge 
to a facility; and this was independent of the underlying comorbid conditions. Mortality was 
increased among older patients. The operational definition for normal sNa in this study was 
138–142 mEq/L. In patients with hospital acquired hyponatremia, the risk of mortality was 15 
times higher among patients with first serum sodium level of 127 mEq/L or less [69]. A larger 
prospective study by Waiker and colleagues with approximately 100,000 individuals followed 
up to 5 years showed that irrespective of the severity of hyponatremia, presence of hyponatre-
mia independently increased risk of dead with an odd ratio of 1.47, 1.32, and 1.33 at the time 
of admission, 1 and 5 year follow-up, respectively. It was more pronounced among patients 
admitted with cardiovascular disease, metastatic cancer, and those admitted for procedures 
related to the musculoskeletal system. They also showed that resolution of hyponatremia 
attenuated the increased risk of mortality [132].
3.5. Complications and outcomes of treatment of hyponatremia
There are no many studies evaluating outcomes of treatment of hyponatremia. Two studies 
evaluated the impact of treatment on mortality among patients with congestive heart failure 
and concluded that treatment confers no mortality benefit, however, there was symptomatic 
improvement and decreased length of stay [94, 95]. Other studies suggested that correction of 
mild hyponatremia could reverse attention and gait deficits [133, 134].
When hyponatremia develops over a slower rate, 24–48 h, the brain cells are able to adapt 
to expel enough of anions and organic solutes along with water to maintain its size. Rapid 
correction of hyponatremia can lead to inability to regain the organic solutes causing osmotic 
demyelination, a process still poorly understood [5].
Osmotic demyelination syndrome (ODS) and central pontine myelinolysis (CPM) are terms 
usually used interchangeably, but they represent separate, not well understood and highly 
feared complications of the treatment of hyponatremia. The effect of rapid correction of hypo-
natremia is termed as ODS and it is specific to the central nervous system and not always 
localized to the pontine region. Extrapontine myelinolysis is as frequent as CPM [135, 136]. 
Risk factors making patients more susceptible to the development of ODS include severity 
and chronicity of hyponatremia, the increment of sNa, the treatment used for sodium cor-
rection, concomitant hypokalemia, presence of liver disease and the nutritional status [98]. A 
small study of 33 patients showed that an increase in sNa to normal or hypernatremic levels 
in the first 48 h, a change in the sNa concentration of >25 mmol/L in the first 48 h, a hypoxic-
anoxic episode, and an elevation of sNa to hypernatremic levels in patients with hepatic 
encephalopathy were associated with CMP. However, rate of correction was not associated 
with demyelination [118].
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The clinical manifestations of ODS are variable depending on the location of demyelination. 
They range from pontine and bulbar symptoms such as dysarthria, dysphagia, and dystonia 
to more severe forms like locked-in state and coma [137]. In the past, prognosis of ODS and 
CMP was considered to be very poor; however, several studies have reported near complete 
neurological recovery. In addition, ODS/CMP are associated with other complications like 
aspiration pneumonia, urinary tract infection, deep venous thrombosis, and pulmonary 
embolism [137–139].
3.6. How can ODS be avoided?
In the absence of an absolute threshold for the rate of correction, it is well accepted that the 
safest rate of correction of hyponatremia is 6–8 mEq/L/day. Brain demyelination has been 
reported over a range of rate of sNa correction of 8–12–18 mEq/L/day [2, 72]. Some inves-
tigators in small, nonrandomized studies suggest concomitant use of desmopressin and 
hypertonic saline for better control of the rate of sNa correction in hyponatremia [140, 141]. 
Experiments on rats have shown little success with the combination regimen of D5W and 
desmopressin for the treatment of overcorrection of hyponatremia [142, 143]. The role of urea 
for ODS have not been well studied.
3.7. Hypernatremia
A difference of the complexity of hyponatremia, the finding of hypernatremia invariably 
denotes hypertonic hyperosmolality and always causes cellular dehydration. It is usually 
defined as a sNa of more than 145 mmol/L. It can be a frequent finding in hospitalized patients 
or high risk patients with poor access to water like the elderly, infants, patients on mechanical 
ventilation, and patients with altered mental status. In the elderly, a physiologic decrease in 
the thirst mechanism have been reported; however, there can be a pathological decrease in 
free water intake as well [60].
In general, clinical manifestations of hypernatremia correlate with the severity of sodium 
abnormalities and are related to central nervous system dysfunction and ranges from weak-
ness, confusion to seizure and coma. In addition, sign of hypovolemia and hemodynamic 
abnormalities can be found on examination.
The complications of hypernatremia vary from mild to life threatening [144]. Brain shrinkage 
induced by hypernatremia can cause vascular rupture, with cerebral bleeding, subarachnoid 
hemorrhage, and permanent neurologic damage or death.
Causes of hypernatremia can be loose classified in two: either net water losses due to gastro-
intestinal or renal etiologies or hypertonic solution administration [144, 145].
3.7.1. Management of hypernatremia
The focus of management is addressing the underlying cause leading to hypernatremia and 
the correction of serum sodium. Initial evaluation includes evaluation of vital signs. In hemo-
dynamically unstable patients, administration of isotonic 0.9% normal saline or balance fluids 
is advised, irrespective of sNa. Goal in those patients is fluid resuscitation hemodynamic 
Fluids and Sodium Imbalance: Clinical Implications
http://dx.doi.org/10.5772/intechopen.79121
19
stabilization. Patient who are hemodynamically stable can be managed with oral or IVF 
replacement. The preferred route for fluid administration is the oral route or a feeding tube; 
otherwise IVF are required. Only hypotonic fluids are recommended, including pure water, 
5% dextrose, and 0.2 or 0.45% sodium chloride. The more hypotonic the infusate, the lower 
the infusion rate required. An easy and efficient way to calculate this is by using Adrogue-
Madias formula, which allows to calculate rate of infusate [144].
Correction rates: similar to management of hyponatremia, and to avoid sudden changes 
in tonicity, the target recommended fall in the sNa concentration is 8–10 mmol/L/day for 
patients with hypernatremia with a goal to reduce the sNa to 145 mmol/L [145, 146].
Pearls:
1. Serum sodium abnormalities are common and carry significant morbidity and mortality.
2. Evaluation of sodium abnormalities should focus in the underlying condition as well as 
management.
3. Following recommended algorithms for evaluation of hyponatremia is advised.
4. Evaluation of volume status in patients with sodium disorders can be a challenge.
5. Needs to keep in consideration the presence of more than one disorder.
6. Resuscitation of an unstable patient takes precedence over correction of sodium levels.
7. There is no rush to correct sNa levels, risk of overcorrection, or rapid increase in sNa can 
lead to serious complications.
4. Conclusion
We reviewed issues related to fluids and sodium disturbance and the clinical implications of 
these issues. The dysregulation of fluid and sodium homeostasis leads to many direct and 
indirect effects and carries significant morbidity and mortality in a wide variety of patients 
and clinical settings. Those range from mild cases of dehydration to more severe cases of 
patients in shock or with severe hypo- or hypernatremia.
Since the high prevalence of these disorders, clinicians in virtually every medical specialty 
will interact with patients requiring fluid administration and need for electrolyte evaluation 
and correction. Appropriate and timely administration of fluids and electrolyte correction 
with focus in avoidance of complications and improvement of outcomes is fundamental.
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Abbreviations
ECF extracellular fluid
ICF intracellular fluid
IVF intravenous fluids
RRT renal replacement therapy
HES hydroxyethyl starches
SID strong ion difference
TBI traumatic brain injury
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